{"id":2996,"date":"2022-09-30T13:06:38","date_gmt":"2022-09-30T11:06:38","guid":{"rendered":"http:\/\/lupusgalicia.org\/?p=2996"},"modified":"2024-06-27T12:18:51","modified_gmt":"2024-06-27T10:18:51","slug":"disponible-el-primer-informe-innovatser-sobre-anifrolumab-en-les","status":"publish","type":"post","link":"https:\/\/lupusgalicia.org\/?p=2996","title":{"rendered":"Disponible el primer informe InnovaTSER"},"content":{"rendered":"\n<p class=\"has-medium-font-size wp-block-paragraph\">Todas las especialidades m\u00e9dicas buscan continuamente f\u00e1rmacos m\u00e1s eficaces y seguros. Este encomiable af\u00e1n por controlar la enfermedad empuja a las empresas farmac\u00e9uticas a una continua innovaci\u00f3n que se traduce en la generaci\u00f3n de f\u00e1rmacos con mecanismos de acci\u00f3n m\u00e1s complejos y dirigidos hacia dianas terap\u00e9uticas espec\u00edficas. En este escenario, con frecuencia, nuevos productos salen&nbsp;al mercado, lo que hace dif\u00edcil al profesional m\u00e9dico mantenerse al d\u00eda de la innovaci\u00f3n terap\u00e9utica.<\/p>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\">Con la finalidad de facilitar a los reumat\u00f3logos la actualizaci\u00f3n sobre los nuevos f\u00e1rmacos, la SER ha puesto en marcha el proyecto InnovaTSER (Innovaci\u00f3n Terap\u00e9utica de la Sociedad Espa\u00f1ola de Reumatolog\u00eda). Esta&nbsp;iniciativa pretende presentar a los reumat\u00f3logos documentos basados en la mejor evidencia disponible sobre la eficacia y seguridad de productos que van a salir al mercado con indicaci\u00f3n en enfermedades reum\u00e1ticas.&nbsp; Los informes InnovaTSER ser\u00e1n&nbsp; elaborados por reumat\u00f3logos expertos en la patolog\u00eda para la que se indican los nuevos compuestos. El objetivo&nbsp;es que estos documentos est\u00e9n disponibles a los 3 meses de que el CHMP (Committee for Medicinal Products for Human Use) de la EMA (European Medicines Agency) haya emitido un informe favorable sobre la nueva indicaci\u00f3n.<\/p>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\">Como criterio de calidad, al igual que se hace con los documentos basados en la evidencia que elabora la SER, los documentos del proyecto InnovaTSER ser\u00e1n sometidos a un proceso de evaluaci\u00f3n p\u00fablica en el que los stakeholders&nbsp;podr\u00e1n presentar alegaciones basadas en la evidencia.<\/p>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\">El documento final que se libera representa la postura de la SER a la luz de los conocimientos cient\u00edficos en el momento de su publicaci\u00f3n. Estos informes ser\u00e1n actualizados cuando la informaci\u00f3n generada por el uso cl\u00ednico del f\u00e1rmaco aconseje su modificaci\u00f3n.<\/p>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\">Con todo ello, desde la Sociedad Espa\u00f1ola de Reumatolog\u00eda nos presentan el primer documento InnovaTSER de anifrolumab en lupus eritematoso sist\u00e9mico (LES), ya que la&nbsp;EMA ha autorizado el uso de este medicamento&nbsp;-bajo el nombre comercial de Saphnelo\u00ae- como tratamiento de LES en combinaci\u00f3n con el tratamiento est\u00e1ndar&nbsp;en pacientes adultos con actividad de moderada a grave de la enfermedad y autoanticuerpos positivos. En concreto, en este informe se puede&nbsp;profundizar en los datos de seguridad, limitaciones, validez y utilidad pr\u00e1ctica, entre otros aspectos, hasta llegar a un posicionamiento terap\u00e9utico.<\/p>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\">Este documento cuenta, adem\u00e1s, con el aval de la Federaci\u00f3n Espa\u00f1ola de Lupus (FELUPUS).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Art\u00edculo de la <a href=\"https:\/\/www.ser.es\/disponible-el-primer-informe-innovatser-sobre-anifrolumab-en-les\/\">Sociedad Espa\u00f1ola de Reumatolog\u00eda<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Documento:  <a href=\"https:\/\/www.ser.es\/wp-content\/uploads\/2022\/09\/InnovaTSER_ANF_def.pdf\">Informe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Todas las especialidades m\u00e9dicas buscan continuamente f\u00e1rmacos m\u00e1s eficaces y seguros. Este encomiable af\u00e1n por controlar la enfermedad empuja a las empresas farmac\u00e9uticas a una continua innovaci\u00f3n que se traduce en la generaci\u00f3n de f\u00e1rmacos con mecanismos de acci\u00f3n m\u00e1s complejos y dirigidos hacia dianas terap\u00e9uticas espec\u00edficas. En este escenario, con frecuencia, nuevos productos salen&nbsp;al [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3001,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[51,4,6,79],"tags":[44,61,19,84,16],"class_list":["post-2996","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actividades","category-en-espana","category-investigacion","category-medicacion","tag-estudios","tag-felupus","tag-informacion","tag-reumatologia","tag-tratamientos"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\r\n<title>Disponible el primer informe InnovaTSER - Asociaci\u00f3n Galega de Lupus<\/title>\r\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\r\n<link rel=\"canonical\" href=\"https:\/\/lupusgalicia.org\/?p=2996\" \/>\r\n<meta property=\"og:locale\" content=\"es_ES\" \/>\r\n<meta property=\"og:type\" content=\"article\" \/>\r\n<meta property=\"og:title\" content=\"Disponible el primer informe InnovaTSER - Asociaci\u00f3n Galega de Lupus\" \/>\r\n<meta property=\"og:description\" content=\"Todas las especialidades m\u00e9dicas buscan continuamente f\u00e1rmacos m\u00e1s eficaces y seguros. Este encomiable af\u00e1n por controlar la enfermedad empuja a las empresas farmac\u00e9uticas a una continua innovaci\u00f3n que se traduce en la generaci\u00f3n de f\u00e1rmacos con mecanismos de acci\u00f3n m\u00e1s complejos y dirigidos hacia dianas terap\u00e9uticas espec\u00edficas. En este escenario, con frecuencia, nuevos productos salen&nbsp;al [&hellip;]\" \/>\r\n<meta property=\"og:url\" content=\"https:\/\/lupusgalicia.org\/?p=2996\" \/>\r\n<meta property=\"og:site_name\" content=\"Asociaci\u00f3n Galega de Lupus\" \/>\r\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LupusGalicia\/\" \/>\r\n<meta property=\"article:published_time\" content=\"2022-09-30T11:06:38+00:00\" \/>\r\n<meta property=\"article:modified_time\" content=\"2024-06-27T10:18:51+00:00\" \/>\r\n<meta property=\"og:image\" content=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2022\/09\/Anifrolumab-e1719483501655.jpg\" \/>\r\n\t<meta property=\"og:image:width\" content=\"1395\" \/>\r\n\t<meta property=\"og:image:height\" content=\"909\" \/>\r\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\r\n<meta name=\"author\" content=\"Agal\" \/>\r\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\r\n<meta name=\"twitter:creator\" content=\"@LupusGalicia\" \/>\r\n<meta name=\"twitter:site\" content=\"@LupusGalicia\" \/>\r\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Agal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\r\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2996#article\",\"isPartOf\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2996\"},\"author\":{\"name\":\"Agal\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665\"},\"headline\":\"Disponible el primer informe InnovaTSER\",\"datePublished\":\"2022-09-30T11:06:38+00:00\",\"dateModified\":\"2024-06-27T10:18:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2996\"},\"wordCount\":463,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/lupusgalicia.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2996#primaryimage\"},\"thumbnailUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2022\/09\/Anifrolumab-e1719483501655.jpg\",\"keywords\":[\"Estudios\",\"Felupus\",\"Informaci\u00f3n\",\"reumatolog\u00eda\",\"Tratamientos\"],\"articleSection\":[\"Actividades\",\"En Espa\u00f1a\",\"Investigaci\u00f3n\",\"medicaci\u00f3n\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/lupusgalicia.org\/?p=2996#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2996\",\"url\":\"https:\/\/lupusgalicia.org\/?p=2996\",\"name\":\"Disponible el primer informe InnovaTSER - Asociaci\u00f3n Galega de Lupus\",\"isPartOf\":{\"@id\":\"https:\/\/lupusgalicia.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2996#primaryimage\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2996#primaryimage\"},\"thumbnailUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2022\/09\/Anifrolumab-e1719483501655.jpg\",\"datePublished\":\"2022-09-30T11:06:38+00:00\",\"dateModified\":\"2024-06-27T10:18:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2996#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lupusgalicia.org\/?p=2996\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2996#primaryimage\",\"url\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2022\/09\/Anifrolumab-e1719483501655.jpg\",\"contentUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2022\/09\/Anifrolumab-e1719483501655.jpg\",\"width\":1395,\"height\":909},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2996#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/lupusgalicia.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Disponible el primer informe InnovaTSER\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lupusgalicia.org\/#website\",\"url\":\"https:\/\/lupusgalicia.org\/\",\"name\":\"Asociaci\u00f3n Galega de Lupus\",\"description\":\"Trabajando para y por las personas con Lupus\",\"publisher\":{\"@id\":\"https:\/\/lupusgalicia.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lupusgalicia.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/lupusgalicia.org\/#organization\",\"name\":\"Asociaci\u00f3n Galega de Lupus\",\"url\":\"https:\/\/lupusgalicia.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png\",\"contentUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png\",\"width\":2560,\"height\":2522,\"caption\":\"Asociaci\u00f3n Galega de Lupus\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/LupusGalicia\/\",\"https:\/\/x.com\/LupusGalicia\",\"https:\/\/www.instagram.com\/lupusgalicia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665\",\"name\":\"Agal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"caption\":\"Agal\"},\"description\":\"AGAL. Asociaci\u00f3n Galega de Lupus. Creada en 1997. Pretendemos dar informaci\u00f3n sobre el Lupus y que la enfermedad deje de ser una gran desconocida; ayudar a familiares y amigos; promover investigaci\u00f3n; divulgar y relacionar a nuestros asociados a trav\u00e9s de Jornadas, la revista Papilio, charlas, reuniones...\",\"sameAs\":[\"http:\/\/www.lupusgalicia.org\"],\"url\":\"https:\/\/lupusgalicia.org\/?author=1\"}]}<\/script>\r\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Disponible el primer informe InnovaTSER - Asociaci\u00f3n Galega de Lupus","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lupusgalicia.org\/?p=2996","og_locale":"es_ES","og_type":"article","og_title":"Disponible el primer informe InnovaTSER - Asociaci\u00f3n Galega de Lupus","og_description":"Todas las especialidades m\u00e9dicas buscan continuamente f\u00e1rmacos m\u00e1s eficaces y seguros. Este encomiable af\u00e1n por controlar la enfermedad empuja a las empresas farmac\u00e9uticas a una continua innovaci\u00f3n que se traduce en la generaci\u00f3n de f\u00e1rmacos con mecanismos de acci\u00f3n m\u00e1s complejos y dirigidos hacia dianas terap\u00e9uticas espec\u00edficas. En este escenario, con frecuencia, nuevos productos salen&nbsp;al [&hellip;]","og_url":"https:\/\/lupusgalicia.org\/?p=2996","og_site_name":"Asociaci\u00f3n Galega de Lupus","article_publisher":"https:\/\/www.facebook.com\/LupusGalicia\/","article_published_time":"2022-09-30T11:06:38+00:00","article_modified_time":"2024-06-27T10:18:51+00:00","og_image":[{"width":1395,"height":909,"url":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2022\/09\/Anifrolumab-e1719483501655.jpg","type":"image\/jpeg"}],"author":"Agal","twitter_card":"summary_large_image","twitter_creator":"@LupusGalicia","twitter_site":"@LupusGalicia","twitter_misc":{"Escrito por":"Agal","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lupusgalicia.org\/?p=2996#article","isPartOf":{"@id":"https:\/\/lupusgalicia.org\/?p=2996"},"author":{"name":"Agal","@id":"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665"},"headline":"Disponible el primer informe InnovaTSER","datePublished":"2022-09-30T11:06:38+00:00","dateModified":"2024-06-27T10:18:51+00:00","mainEntityOfPage":{"@id":"https:\/\/lupusgalicia.org\/?p=2996"},"wordCount":463,"commentCount":0,"publisher":{"@id":"https:\/\/lupusgalicia.org\/#organization"},"image":{"@id":"https:\/\/lupusgalicia.org\/?p=2996#primaryimage"},"thumbnailUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2022\/09\/Anifrolumab-e1719483501655.jpg","keywords":["Estudios","Felupus","Informaci\u00f3n","reumatolog\u00eda","Tratamientos"],"articleSection":["Actividades","En Espa\u00f1a","Investigaci\u00f3n","medicaci\u00f3n"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/lupusgalicia.org\/?p=2996#respond"]}]},{"@type":"WebPage","@id":"https:\/\/lupusgalicia.org\/?p=2996","url":"https:\/\/lupusgalicia.org\/?p=2996","name":"Disponible el primer informe InnovaTSER - Asociaci\u00f3n Galega de Lupus","isPartOf":{"@id":"https:\/\/lupusgalicia.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lupusgalicia.org\/?p=2996#primaryimage"},"image":{"@id":"https:\/\/lupusgalicia.org\/?p=2996#primaryimage"},"thumbnailUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2022\/09\/Anifrolumab-e1719483501655.jpg","datePublished":"2022-09-30T11:06:38+00:00","dateModified":"2024-06-27T10:18:51+00:00","breadcrumb":{"@id":"https:\/\/lupusgalicia.org\/?p=2996#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lupusgalicia.org\/?p=2996"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/lupusgalicia.org\/?p=2996#primaryimage","url":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2022\/09\/Anifrolumab-e1719483501655.jpg","contentUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2022\/09\/Anifrolumab-e1719483501655.jpg","width":1395,"height":909},{"@type":"BreadcrumbList","@id":"https:\/\/lupusgalicia.org\/?p=2996#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/lupusgalicia.org\/"},{"@type":"ListItem","position":2,"name":"Disponible el primer informe InnovaTSER"}]},{"@type":"WebSite","@id":"https:\/\/lupusgalicia.org\/#website","url":"https:\/\/lupusgalicia.org\/","name":"Asociaci\u00f3n Galega de Lupus","description":"Trabajando para y por las personas con Lupus","publisher":{"@id":"https:\/\/lupusgalicia.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lupusgalicia.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/lupusgalicia.org\/#organization","name":"Asociaci\u00f3n Galega de Lupus","url":"https:\/\/lupusgalicia.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/","url":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png","contentUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png","width":2560,"height":2522,"caption":"Asociaci\u00f3n Galega de Lupus"},"image":{"@id":"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LupusGalicia\/","https:\/\/x.com\/LupusGalicia","https:\/\/www.instagram.com\/lupusgalicia\/"]},{"@type":"Person","@id":"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665","name":"Agal","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","caption":"Agal"},"description":"AGAL. Asociaci\u00f3n Galega de Lupus. Creada en 1997. Pretendemos dar informaci\u00f3n sobre el Lupus y que la enfermedad deje de ser una gran desconocida; ayudar a familiares y amigos; promover investigaci\u00f3n; divulgar y relacionar a nuestros asociados a trav\u00e9s de Jornadas, la revista Papilio, charlas, reuniones...","sameAs":["http:\/\/www.lupusgalicia.org"],"url":"https:\/\/lupusgalicia.org\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/2996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2996"}],"version-history":[{"count":3,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/2996\/revisions"}],"predecessor-version":[{"id":4495,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/2996\/revisions\/4495"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/media\/3001"}],"wp:attachment":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}